(MENAFN- GlobeNewsWire - Nasdaq) PHILADELPHIA, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time AAV gene therapies for major chronic pet health conditions, today announced that Mark Heffernan, Chief Executive Officer, will present at two upcoming investor conferences.
- Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 1, 2020 at 4:00 p.m. ET
- Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 2:00 p.m. ET
About Scout Bio
Scout Bio is a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time AAV gene therapies for major chronic pet health conditions. Scout has an exclusive research and development collaboration with the University of Pennsylvania's Gene Therapy Program, which is a global leader in gene therapy research and development for nearly three decades. Scout's therapeutics are designed to induce long-term expression of therapeutic proteins in pet patients using AAV vector technology. Scout Bio is a private company headquartered in Philadelphia, Pennsylvania. For more information, please visit [To enable links contact MENAFN] .
For further information, please contact:
Investor s :
Sarah McCabe
Stern Investor Relations, Inc.
212.362.1200
Media:
Fran Gaconnier
Scout Bio
214.417.4142
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.